An Update on Intracerebral Hemorrhage

Study Overview
=================
Brief Summary
-----------------
The intracerebral hemorrhage study is a multicenter , combination of prospective and retrospective observational cohort study led by Dr. Muhammad Junaid Akram, PhD scholar at Chongqing Medical University. Prof Dr. Qi Li will be the senior consultant for the study. The study will be focusing on natural history, epidemiological , radiological, rehabilitative and clinical aspects as well as the effect of various treatments on the hemorrhagic patients. The study related data of the patients diagnosed with intracerebral hemorrhage will be collected in prospective and retrospective ways. The prognostic data for the patients will be assembled and collected via using different outcome measures at different points of time.

Detailed Description
-----------------
The study will be used to address the several key issues related to intracerebral hemorrhage. The demographics, scores based upon disease severity , mRS, GCS, NIHSS scores will be recorded at baseline and in the prospective and retrospective ways. The data obtained from the registered patients will be used for future use , critical review by expert neurologists, neurorehabilitative experts for further use and review.

Official Title
-----------------
An Update on Intracerebral Hemorrhage - A Cohort Study

Conditions
-----------------
Intracerebral Hemorrhage, Stroke, Hematoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Patients willing to participate via signing a consent form' Patients diagnosed with CT-Confirmed spontaneous intracerebral hemorrhage (ICH) Patients willing to participate in the follow up assessment Exclusion Criteria: Not willing to participate Secondary ICH to hemorrhagic infarction or tumor bleeding etc. Traumatic ICH

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Benign Hematoma<br>Patients (having novel image markers or clinical features) suggestive of a benign hematoma relatively , that is having relatively good prognostic outcome and less likely to expand. | |
| Malignant Hematoma<br>Patients (having novel image markers or clinical features) suggestive of a malignant hematoma relatively, that is more likely to expand and have poor prognostic outcome. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hematoma volume growth at 24 hours | To assess early hematoma volume growth at 24 hours | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional outcome at 3 months assessed by modified Rankin Scale | Assess functional outcome at 3 months by using mRS | 3 months | 
| Early neurological deterioration assessed by NIHSS score at 24 hours | To assess early neurological deterioration by using NIHSS score at 24 hours | 24 hours | 
| Early neurological deterioration assessed by NIHSS score at 48 hours | To assess early neurological deterioration by using NIHSS score at 48 hours | 48 hours | 
| Early neurological deterioration assessed by NIHSS score at 72 hours | To assess early neurological deterioration by using NIHSS score at 72 hours | 72 hours | 
| Perihematomal edema volume measurement at 24 hours | To measure the perihematomal edema volume growth at 24 hours | 24 hours | 
| Perihematomal edema volume measurement at 48 hours | To measure the perihematomal edema volume growth at 48 hours | 48 hours | 
| Perihematomal edema volume measurement at 72 hours | To measure the perihematomal edema volume growth at 72 hours | 72 hours | 
| Intraventricular hemorrhage growth | To assess the presence of IVH at 24 hours | 24 hours | 
| Major thrombotic events | To assess the thrombotic events 2 weeks after admission | 2 weeks |